Posted by Michael Wonder on 20 Feb 2024
Medera’s Sardocor announces fast track designation and dosing of 3 patients in first in human HFpEF gene therapy trial
14 February 2024 - In the Phase 1/2A clinical trial for SRD-001, an adeno-associated virus mediated first in human gene therapy for heart failure with preserved ejection fraction, Sardocor successfully injected the first 3 patients via our proprietary intracoronary delivery technique.
The US FDA has granted fast track designation to Sardocor’s investigational gene therapy treatment for Heart failure with preserved ejection fraction.
